Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 127   

Articles published

GSK 1,636.87 +3.37 (0.21%)
price chart
GlaxoSmithKline plc (GSK) Rating Reiterated by Citigroup Inc.
GlaxoSmithKline plc logo GlaxoSmithKline plc (LON:GSK)'s stock had its “buy” rating reissued by stock analysts at Citigroup Inc. in a research report issued to clients and investors on Friday.
GlaxoSmithKline PLC (GSK) Upgraded by Zacks Investment Research to "Buy ...  BBNS
What GlaxoSmithKline plc's choice of CEO means for shareholders
On Tuesday, GlaxoSmithKline(LSE: GSK) announced -- with much fanfare -- that it had selected Emma Walmsley to become the group's new chief executive officer when its current boss Sir Andrew Witty steps down next year.
Is Sinclair Pharma plc a better bet than GlaxoSmithKline plc?
The pharmaceuticals business is like two sectors in one -- we have the world's giant blockbuster drug companies, and the much smaller firms developing new technologies and looking for a slice of the pie.
Should you buy GlaxoSmithKline plc after its change in CEO?
GlaxoSmithKline(LSE: GSK) has announced that its CEO, Andrew Witty, will be replaced by Emma Walmsley. She's the current CEO of its Consumer Healthcare division and will take over the reins of the company in March 2017.
GlaxoSmithKline's choice of new boss disappoints City  Proactive Investors UK
Glaxo Names Consumer Head Emma Walmsley to Succeed Witty as CEO  Bloomberg
Confluence Investment Management LLC Raises Position in GlaxoSmithKline PLC (GSK)
GlaxoSmithKline PLC logo Confluence Investment Management LLC boosted its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) by 12.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange ...
GlaxoSmithKline plc (GSK) Receives Buy Rating from Citigroup Inc.  BBNS
GlaxoSmithKline PLC (GSK) Coverage Initiated at Piper Jaffray Cos.  Community Financial News
GlaxoSmithKline plc Broker Press
GlaxoSmithKline plc. GlaxoSmithKline supplies an estimated seven per cent of the world's pharmaceutical market and has six major disease areas - asthma, virus control, infections, mental health, diabetes and digestive conditions.
Better Buy: GlaxoSmithKline plc vs. AbbVie
Within the ecosystem of large-cap drug stocks, AbbVie (NYSE:ABBV) and GlaxoSmithKline (NYSE:GSK) are easily top dogs when it comes to their respective dividend yields.
Why Vectura group plc and GlaxoSmithKline plc could be the perfect combination
Shares in Vectura (LSE: VEC) are charging higher today after the company issued an upbeat trading statement ahead of its AGM to be held later today.
Is Dechra Pharmaceuticals plc a better buy than GlaxoSmithKline plc after ...
Pharmaceutical giants Dechra Pharmaceuticals (LSE: DPH) and GlaxoSmithKline (LSE: GSK) took divergent paths in Monday morning business despite both releasing positive updates.
Dechra Pharmaceuticals plc Still Leads GlaxoSmithKline plc, AstraZeneca plc ...  Investomania (blog)
Form 6-K GLAXOSMITHKLINE PLC For: Sep 23
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the submission of a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) by Janssen Biotech, Inc., (JBI), seeking approval of a subcutaneous formulation of ...
GlaxoSmithKline Files US Regulatory Application for Sirukumab in Rheumatoid ...  Nasdaq
GSK Announces US Regulatory Submission For Sirukumab In Rheumatoid Arthritis  RTT News